scholarly journals Clinical Options for the Reduction of Elevated Intraocular Pressure

2012 ◽  
Vol 4 ◽  
pp. OED.S4909 ◽  
Author(s):  
Laura Crawley ◽  
Sohaib M. Zamir ◽  
Maria F. Cordeiro ◽  
Li Guo
Keyword(s):  
Intraocular Pressure ◽  
Clinical Practice ◽  
Chronic Disease ◽  
Ocular Hypertension ◽  
New Technologies ◽  
Pharmacological Agents ◽  
Elevated Intraocular Pressure ◽  
Laser Treatments

Elevated IOP in clinical practice is usually seen in glaucoma or ocular hypertension. Glaucoma affects 60 million people worldwide and 8.4 million are bilaterally blind from this chronic disease. 1 Options for reducing IOP rely on pharmacological agents, laser treatments and surgery which may be penetrating or non-penetrating. The last twenty years has seen significant changes in all of these strategies. This review aims to cover these clinical options and introduce some of the new technologies currently in development for the clinical lowering of IOP.

scholarly journals Novel free radical scavengers protect retinal cells and decrease elevated intraocular pressure in a rat ocular hypertension model

2008 ◽  
Vol 22 (S1) ◽  
Author(s):  
Alireza Hosseini ◽  
Frank A. Lattanzio ◽  
Karl A. Schellenberg ◽  
Sandeep S Samudre ◽  
James Shaeffer ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Free Radical ◽  
Ocular Hypertension ◽  
Free Radical Scavengers ◽  
Radical Scavengers ◽  
Retinal Cells ◽  
Elevated Intraocular Pressure

scholarly journals Oral administration of a dual ETA/ETB receptor antagonist promotes neuroprotection in a rodent model of glaucoma

2020 ◽  
Author(s):  
Nolan R. McGrady ◽  
Dorota L. Stankowska ◽  
Hayden B. Jefferies ◽  
Raghu R. Krishnamoorthy
Keyword(s):  
Intraocular Pressure ◽  
Oral Administration ◽  
Receptor Antagonist ◽  
Ocular Hypertension ◽  
Retinal Ganglion Cells ◽  
Ganglion Cells ◽  
Brown Norway ◽  
Retinal Ganglion ◽  
Elevated Intraocular Pressure ◽  
Iop Elevation

AbstractPurposeGlaucoma is a neurodegenerative disease associated with elevated intraocular pressure and characterized by optic nerve axonal degeneration, cupping of the optic disc and loss of retinal ganglion cells (RGCs). The endothelin (ET) system of vasoactive peptides (ET-1, ET-2, ET-3) and their G-protein coupled receptors (ETA and ETB receptors) have been shown to be contributors to the pathophysiology of glaucoma. The purpose of this study was to determine if administration of the endothelin receptor antagonist, macitentan, after the onset of IOP elevation, was neuroprotective to retinal ganglion cells in ocular hypertensive rats.MethodsBrown Norway rats were subjected to the Morrison model of ocular hypertension by injection of hypertonic saline through episcleral veins. Macitentan (5 and 10 mg/kg body wt/day) was administered orally following the elevation of IOP and rats with IOP elevation were maintained for 4 weeks. RGC function was determined by pattern electroretinography at 2 and 4 weeks post IOP elevation. Rats were euthanized by approved humane methods and retinal flat-mounts generated were immunostained with RGC-selective markers RBPMS and Brn3a. RGC counts were conducted in a masked manner.ResultsA significant protection of retinal ganglion cells against cell loss was found following oral administration of macitentan (5 and 10 mg/kg body wt/day) in rats with elevated intraocular pressure. In addition, treatment with macitentan was able to preserve RGC function as measured by pattern ERG analysis.ConclusionsMacitentan was able to promote neuroprotection independent of IOP-lowering suggesting that this could complement existing treatments to prevent neurodegeneration during ocular hypertension. The findings presented have implications for the use of macitentan as an oral formulation to promote neuroprotection in glaucoma patients.

scholarly journals Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension

2011 ◽  
Vol 3 ◽  
pp. OED.S4253 ◽  
Author(s):  
Clyde Schultz
Keyword(s):  
Intraocular Pressure ◽  
Side Effects ◽  
Receptor Antagonist ◽  
Ocular Hypertension ◽  
Clinical Studies ◽  
Open Angle Glaucoma ◽  
Pressure Control ◽  
Open Angle ◽  
Elevated Intraocular Pressure ◽  
Fp Receptor

Tafluprost is an FP receptor antagonist that has been shown in clinical studies in Europe and Japan to be extremely useful in treating elevated intraocular pressure and glaucoma. The drug is well tolerated and appears to be at least equal in effectiveness and perhaps superior to other protanoids for routine use comparison to be superior to other treatments for the elevated IOP as the side effects and other related symptomology appear to be less, while maintaining a level of pressure control for prolonged periods.

Sign in / Sign up

Export Citation Format

Share Document